# Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus Erythematosus

> **NCT02106897** · PHASE1 · COMPLETED · sponsor: **Biogen** · enrollment: 109 (actual)

## Conditions studied

- Systemic Lupus Erythematosus
- Healthy Volunteers

## Interventions

- **DRUG:** BIIB059 (litifilimab)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02106897
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-30
- **Primary completion:** 2016-05-24
- **Final completion:** 2016-05-24
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2023-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02106897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02106897, "Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02106897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*